Yahoo Finance’s Daniel Howley joins the Live show to discuss the pause in construction for Amazon’s second headquarters in Arlington, VA. Read More...
MarketWatch
Veru stock plummets toward 2 1/2-year low after FDA denies EUA request for COVID-19 treatment
Share of Veru Inc. (VERU) plunged 31.0% toward a 2 1/2-year low in premarket Friday, after the U.S. Food and Drug Administration turned down the biopharmaceutical company’s request for Emergency Use Authorization (EUA) for sabizabulin, its treatment for hospitalized patients with COVID-19 who are at high risk for Acute Respiratory Distress Syndrome (ARDS). The company said that although the FDA declined the EUA request, “the FDA remains committed to working with the company for the development of sabizabulin.” Separately, the company expects to soon provide details of the timing and design of a proposed confirmatory Phase 3 study it submitted, that could support a new EUA authorization.
Add Comment